Special Access Program for drugs: Guidance document for industry and practitioners
This guidance document explains the regulatory information requirements and conditions for practitioners and manufacturers when drugs are requested through the Special Access Program (SAP). It explains SAP's mandate, intent and scope, and outlines the responsibilities of practitioners and manufacturers.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Special Access Program for drugs: Guidance document for industry and practitionersHTMLEnglish publication HTML
-
Special Access Program for drugs: Guidance document for industry and practitionersHTMLFrench publication HTML
Similar records